Oxygen Biotherapeutics secures first license for glucose biosensor
This article was originally published in Clinica
Executive Summary
Costa Mesa, California-based Oxygen Biotherapeutics has signed its first licensing deal for its glucose biosensor technology with Glucometrics. The licence allows Glucometrics to use the Oxycyte perfluorocarbon therapeutic oxygen carrier technology for applications involving the measurement and monitoring of glucose levels in diabetic patients. In exchange, Oxygen Biotherapeutics will receive Glucometrics stock and royalties based on the worldwide net revenues from the products resulting from the deal. Further financial details were not disclosed.